Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31

Yahoo FinanceDec 18 08:38 ET

BioAtla Presents Data on Mecbotamab Vedotin in Advanced NSCLC

TipRanksDec 16 08:25 ET

BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...

BenzingaDec 16 08:10 ET

Express News | Bioatla Presented Data Characterizing Mutated Kras Genotype and Clinical Outcomes in Patients With Advanced Nsclc Treated With Mecbotamab Vedotin (Mec-V), a Cab-Axl-ADC, at the Iaslc 2024 Hot Topic in Basic & Translational Science Meeting

ReutersDec 16 08:00 ET

Express News | BioAtla Shares Are Trading Lower. The Stock May Be Reacting to the Scion Asset Management 13F Filing Disclosing an Exit From Their Position in the Company

BenzingaNov 14 15:38 ET

Express News | Scion Asset Management 13F Shows Exited Position In Hudson Pacific Properties, Previously Holding 1,144,435 Shares; Exited Position In BioAtla, Previously Holding 633,959 Shares

BenzingaNov 14 14:33 ET